Search | Clinical Trials Finder

Conditions: SGA, Turner Syndrome, Noonan Syndrome, ISS
Interventions: Somapacitan, Norditropin®; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 2 Years to 10 Years
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 35
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more

Conditions: Adult Growth Hormone Deficiency
Interventions: Somapacitan; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 29
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Interventions: Serostim; Biological
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Palm Beach, California + 18 more

Conditions: Growth Hormone Disorder, Growth Hormone Deficiency in Children
Interventions: somatropin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 21
States / cities: Los Angeles, California • Wilmington, Delaware • Washington D.C., District of Columbia + 15 more

Conditions: Growth Hormone Disorder, Adult Growth Hormone Deficiency
Interventions: somapacitan, somatropin, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 23 Years to 79 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 23 more

Conditions: Primary Insulin-like Growth Factor-1 Deficiency
Interventions: mecasermin [rDNA origin] injection; Biological
Lead sponsor: Ipsen; Industry
Eligibility: Not listed
Enrollment: 1,378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Basking Ridge, New Jersey

Conditions: Acromegaly
Interventions: Somatuline Autogel (lanreotide acetate), Home administration; Drug · Behavioral
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 13
States / cities: La Mesa, California • Los Angeles, California • Denver, Colorado + 8 more

Conditions: Growth Hormone Deficiency
Interventions: NuSpin, Somatropin; Device · Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 2 Years to 14 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 11 more

Conditions: Growth Hormone Deficiency
Interventions: Somatropin; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 3 Years to 14 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 33
States / cities: Little Rock, Arkansas • Orange, California • Sacramento, California + 28 more

Conditions: Growth Hormone Deficiency in Children
Interventions: Somapacitan, Norditropin®; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Up to 11 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Madera, California + 24 more

Conditions: Growth Hormone Deficiency (GHD)
Interventions: Saizen®; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: US Medical Information, Massachusetts

Conditions: Short Bowel Syndrome
Interventions: Somatropin, Seven Day Food Diary, Blood Tests (standard of care), Fasting, Sugar Permeability Test, Urine Collection; Drug · Procedure · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Growth Hormone Disorder, Growth Hormone Deficiency in Children
Interventions: somapacitan, Norditropin® FlexPro® pen; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 2 Years to 10 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Madera, California + 18 more

Conditions: Growth Hormone Disorder, Adult Growth Hormone Deficiency, Healthy
Interventions: somatropin, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 20 Years to 50 Years · Male only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Growth Disorder, Healthy
Interventions: Norditropin® FlexPro® pen, Genotropin Pen®; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteer Study
Interventions: Intranasal octreotide acetate, Subcutaneous octreotide acetate, Growth hormone-releasing hormone, Arginine hydrochloride; Drug · Diagnostic Test
Lead sponsor: Dauntless Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hypopituitarism
Interventions: Arimidex (Anastrozole), Placebo, Growth Hormone; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 11 Years to 18 Years · Male only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Interventions: Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector; Combination Product
Lead sponsor: Ascendis Pharma A/S; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 19
States / cities: Palo Alto, California • Sacramento, California • Aurora, Colorado + 15 more

Conditions: Genetic Disorder, Prader-Willi Syndrome, Growth Disorder, Idiopathic Short Stature, Healthy
Interventions: somatropin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Growth Hormone Deficiency
Interventions: LUM-201, rhGH Norditropin® pen (34 µg/kg); Drug
Lead sponsor: Lumos Pharma; Industry
Eligibility: 3 Years to 12 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 27
States / cities: Sacramento, California • San Diego, California • Greenwood Village, Colorado + 24 more

Conditions: Gastroparesis
Interventions: Growth Hormone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Phoenix, Arizona • Scottsdale, Arizona

Conditions: Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
Interventions: Somatropin (DNA origin); Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 5 Years to 17 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Childhood-onset Growth Hormone Deficiency, Pituitary Dwarfism
Interventions: recombinant human growth hormone; Biological
Lead sponsor: EMD Serono; Industry
Eligibility: 13 Years to 25 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 9
States / cities: Orange, California • Jacksonville, Florida • Orlando, Florida + 6 more

Conditions: Growth Hormone Disorder, Pituitary Dwarfism, Hypopituitarism
Interventions: somatropin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Up to 18 Years
Enrollment: 22,960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2016
U.S. locations: 1
States / cities: Plainsboro, New Jersey

Search by objective public record fields.

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information

Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome

Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device

A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study

rHGH and Intestinal Permeability in Intestinal Failure

Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin

A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects

Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers

Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers

Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)

Growth Hormone for the Treatment of Gastroparesis

Clinical Trial of Growth Hormone in MPS I, II, and VI

Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency

An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)